This study is a multi-site open-label randomized comparative effectiveness trial of a 28-day
formulation of extended-release buprenorphine (XR-BUP) versus treatment as usual (TAU) for
hospitalized patients with a moderate or severe opioid use disorder (OUD) seen by an
addiction consultation service (ACS) and agreeing to initiate a medication for OUD (MOUD).
Participants will be randomly assigned to XR-BUP or TAU to be received within 72 hours of
anticipated hospital discharge. Follow up will occur at approximately 34, 90, and 180 days
following hospital discharge.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hennepin Healthcare Research Institute
Collaborators:
National Institute on Drug Abuse (NIDA) The Emmes Company, LLC